BiotechTube
Omixon

Omixon

Budapest, Hungary· Est.
omixon.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $15M

Overview

Omixon is a specialized diagnostics company focused on transitioning the HLA typing community from traditional methods to high-resolution Next-Generation Sequencing. Its core offerings are integrated NGS assay kits and proprietary analysis software designed for clinical histocompatibility labs, enabling more accurate matching for transplant patients. The company has achieved significant global adoption, with over 50 labs using its products in clinical routine. In 2024, Omixon was acquired by Werfen, a global in-vitro diagnostics company, integrating it into a larger commercial and regulatory framework.

Transplantation

Technology Platform

Integrated NGS-based HLA genotyping platform combining wet-lab assay kits (for Illumina short-read and Oxford Nanopore long-read sequencers) with proprietary analysis software for high-resolution, full-gene typing.

Funding History

2
Total raised:$15M
Series B$10M
Series A$5M

Opportunities

The global transition of histocompatibility labs to NGS creates a sustained replacement market.
The acquisition by Werfen provides a powerful global commercial and distribution channel for rapid scale-up.
Long-read sequencing technology (NanoTYPE) positions the company at the forefront of the next technical evolution in clinical HLA typing.

Risk Factors

Integration into the larger Werfen organization could slow innovation or cause key talent attrition.
The clinical diagnostics market is competitive and regulated, requiring continuous investment to maintain technological lead and achieve new regulatory clearances (e.g., IVDR for NanoTYPE).

Competitive Landscape

Omixon competes in the specialized HLA NGS market against companies like CareDx (AlloSeq), Thermo Fisher (One Lambda), and other diagnostic firms. Its differentiation lies in its dedicated software, full-gene coverage, and early bet on long-read sequencing. The Werfen acquisition provides a significant commercial advantage over smaller pure-play competitors.

More companies in Diagnostics & Precision Medicine →More companies in Hungary →